India, Jan. 14 -- India's pharmaceutical sector continues to remain an attractive space for investors, supported by strong domestic demand, export opportunities, and improving long-term growth visibility. The sector is expected to deliver double-digit revenue growth, with momentum likely to strengthen in the second half of CY26. While near-term challenges exist, especially for companies with higher exposure to the US market, the overall outlook for Indian pharma remains positive.

Against this backdrop, Jefferies, a global brokerage firm, has turned constructive on select Indian pharma stocks and highlighted a high growth potential of up to 31 percent in some companies. The brokerage expects domestic business growth to stay steady, provid...